Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland.

The median intra-individual reduction in BMI-SDS was −0.20 SDS (IQR −0.28 to −0.10, full range −1.0 to 0.1), which was highly significant (Wilcoxon signed-rank test p = 0.0003) with a large effect size (r b = −0.77).

also in 132,142 other papers